Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00830024 · ClinicalTrials.gov registry record · Phase 1

Alprazolam Extended-Release 3mg Tablets Bioequivalence Study Under Non-fasting Conditions

A Phase 1 study of Healthy, sponsored by Teva Pharmaceuticals U.

Completed
Registry status
Phase 1
Development phase
36
Enrollment target
2
Study locations

NCT00830024: Completed Phase 1 study of Healthy, sponsored by Teva Pharmaceuticals U.

NCT00830024 is a Phase 1 study of Healthy that has completed, run by Teva Pharmaceuticals U. The registered enrollment target is 36 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (94% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00830024, a Phase 1 study of Healthy, has completed, sponsored by Teva Pharmaceuticals U.

COMPLETED
Registry status
Phase 1
Development phase
36 participants
Enrollment target
2
Study locations

Study Summary

This study will compare the relative bioavailability (rate and extent of absorption) of 3 mg Alprazolam Extended Release Tablets manufactured and distributed by TEVA Pharmaceuticals USA with that of 3 mg XANAX XR® Tablets by Pharmacia \& Upjohn Company following a single oral dose (1 x 3 mg extended release tablet) in healthy adult subjects administered under non-fasting conditions.

Primary Outcome

Bioequivalence based on Cmax

Conditions Studied

Healthy

Interventions

  • DRUG Alprazolam Extended-Release 3 mg Tablets

Study Locations (2)

Minnesota

  • PRACS Institute, Ltd. - East Grand Forks

North Dakota

  • PRACS Institute, Ltd. - Fargo

Trial Details

FieldValue
Enrollment Target 36 participants
Start Date 2005-06
Est. Completion 2005-06
Phase Phase 1
Teva Pharmaceuticals U

19 total trials

What the finished NCT00830024 record still lists

NCT00830024 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (94% lower).

The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 1 intervention - of which Alprazolam Extended-Release 3 mg Tablets is the first listed.

NCT00830024 reports a single indexed study location in Minnesota, North Dakota.

Frequently Asked Questions

What is clinical trial NCT00830024 about?

NCT00830024 is a clinical study titled "Alprazolam Extended-Release 3mg Tablets Bioequivalence Study Under Non-fasting Conditions". This study will compare the relative bioavailability (rate and extent of absorption) of 3 mg Alprazolam Extended Release Tablets manufactured and distributed by TEVA Pharmaceuticals USA with that of 3 mg XANAX XR® Tablets by Pharmacia \& Upjohn Company following a single oral dose (1 x 3 mg extended...

What is the current status of trial NCT00830024?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2005-06. Estimated completion is 2005-06.

What conditions does trial NCT00830024 study?

This clinical trial studies the following conditions: Healthy.

What interventions are being tested in trial NCT00830024?

The interventions under investigation include: Alprazolam Extended-Release 3 mg Tablets (DRUG).

Who is sponsoring clinical trial NCT00830024?

This trial is sponsored by Teva Pharmaceuticals U, which has 19 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00830024 being conducted?

This trial has 2 study locations across Minnesota, North Dakota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Healthy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00830024's enrollment target sits among peer trials

36 595th of 1090 higher than 469 of 1,090 other Healthy trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Healthy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00929006 · 36 participants · Early Phase 1

    Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism

  • NCT01891318 · 36 participants · Phase 1

    Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study

  • NCT02291848 · 36 participants · Phase 1

    Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma

  • NCT02366819 · 36 participants · Phase 4

    Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT00830024, the US trial registry maintained by the National Library of Medicine. NCT00830024 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.